AUA Guidelines Upgrade Strengthen Aquablation Adoption Case for PROCEPT BioRobotics

What happened

The American Urological Association updated its guidelines to strengthen the recommendation for Aquablation therapy in treating BPH for prostate volumes 30–80 mL, providing an important external validation for PROCEPT BioRobotics. This news reinforces the clinical evidence advantage that PROCEPT has touted, potentially accelerating surgeon adoption and hospital committee approvals. However, the company's near-term stock performance remains tied to execution metrics such as handpiece utilization, pricing discipline, and operating cash burn, which have not yet shown consistent improvement. In Q1 2026, PROCEPT reported strong procedure growth of ~30% YoY and improved handpiece ASP, but operating expenses grew faster, leading to increased cash burn and a net loss. The guideline upgrade adds a long-term tailwind but does not address the immediate need for PROCEPT to demonstrate operating leverage and narrow its losses.

Implication

The guidelines strengthen the adoption narrative and could support higher procedure growth over 12-24 months, potentially lowering the risk of utilization decline. However, the stock still trades on near-term operational execution; investors should focus on Q2 2026 metrics—handpieces sold as % of procedures must sustain ~95%+, handpiece ASP above $3,500, and adjusted EBITDA loss improving from Q1’s $(18.1)m. If PROCEPT delivers on these, the guideline upgrade adds conviction to the bull case. If not, the thesis breaks regardless of guideline support. The extended timeline for operating leverage realization remains the dominant risk.

Thesis delta

The AUA guideline upgrade incrementally strengthens PROCEPT’s clinical differentiation and supports the long-term adoption thesis, but it does not change the near-term investment framework centered on operating leverage and cash burn. The thesis shifts from 'relying solely on procedure growth' to 'procedure growth now has an additional accelerator, but the onus remains on margin improvement and cost control.' The fundamental risk of dilution and covenant triggers persists until cash burn demonstrably improves.